Chronic HCV infection is a leading cause of liver-related morbidity and mortality. In 2011, treatment options for patients infected with HCV genotype 1 changed dramatically with the approval of two nonstructural protein 3 protease inhibitors—boceprevir and telaprevir—by the FDA and the European Medicines Agency.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195–1206 (2011).
Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405–2416 (2011).
Bacon, B. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207–1217 (2011).
Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417–2428 (2011).
Zeuzem, S. et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 141, 2047–2055 (2011).
Zeuzem, S. et al. The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C. Hepatology http://dx.doi.org/10.1002/hep.24744.
Di Bisceglie, A. et al. VX-222 with TVR alone or in combination with peginterferon alfa2a and ribavirin in treatment-naive patients with chronic hepatitis C: ZENITH study interim results [abstract]. J. Hepatol. 54, S540 (2011).
Lok, A. S. et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders [abstract]. J. Hepatol. 54, S536 (2011).
Chayama, K. et al. Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responder [LB-4]. Hepatology 54 (Suppl. 1), 100A (2011).
Gane, E. et al. Once daily PSI-7977 plus RBV: pegylated interferon-ALFA not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 [abstract 34]. Hepatology 54 (Suppl. 1), 377A (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W. P. Hofmann has been a speaker for Bristol-Meyers Squibb, Gilead, MSD and Janssen Cilag. W. P. Hofmann has been a speaker for and received grant/research support from Roche. S. Zeuzem has been a consultant for and received grant/research support from Abbott, Achillion, Boehringer Ingelheim, Bristol-Meyers Squibb, Gilead, iTherX, Merck, Pharmasset, Roche, Santaris, Tibotec and Vertex. S Zeuzem has been a speaker for Bristol-Meyers Squibb, Gilead, Merck, Roche, Tibotec and Vertex.
Rights and permissions
About this article
Cite this article
Hofmann, W., Zeuzem, S. A new standard of care and the race towards IFN-free therapy. Nat Rev Gastroenterol Hepatol 9, 67–68 (2012). https://doi.org/10.1038/nrgastro.2011.249
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.249
